The risk for locoregional recurrence increased with younger age, bigger tumors, and larger numbers of confirmed pathologically involved axillary nodes.
Predictors of locoregional recurrences (LRRs) after preoperative systemic therapy in patients with early-stage breast cancer have been suggested from small, single-institution studies. But few large data sets are available for careful examination of this issue.
Now, investigators have conducted a combined analysis of the National Surgical Adjuvant Breast and Bowel Project B-18 and B-27 trials (J Clin Oncol 2008; 26:778) to identify LRR predictors in 3088 patients with operable breast cancer. In the B-18 trial, patients were randomized to four cycles of doxorubicin and cyclophosphamide (AC), either preoperatively or postoperatively. In the B-27 trial, patients were randomized to three treatments: four cycles of AC followed by surgery, four cy…
Reviewing Author
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)